219 related articles for article (PubMed ID: 36382108)
1. Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy.
Gardner SL; Tarapore RS; Allen J; McGovern SL; Zaky W; Odia Y; Daghistani D; Diaz Z; Hall MD; Khatib Z; Koschmann C; Cantor E; Kurokawa R; MacDonald TJ; Aguilera D; Vitanza NA; Mueller S; Kline C; Lu G; Allen JE; Khatua S
Neurooncol Adv; 2022; 4(1):vdac143. PubMed ID: 36382108
[TBL] [Abstract][Full Text] [Related]
2. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
[TBL] [Abstract][Full Text] [Related]
3. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
[TBL] [Abstract][Full Text] [Related]
4. First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report.
Hall MD; Odia Y; Allen JE; Tarapore R; Khatib Z; Niazi TN; Daghistani D; Schalop L; Chi AS; Oster W; Mehta MP
J Neurosurg Pediatr; 2019 Apr; 23(6):719-725. PubMed ID: 30952114
[TBL] [Abstract][Full Text] [Related]
5. Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma.
Odia Y; Koschmann C; Vitanza NA; de Blank P; Aguilera D; Allen J; Daghistani D; Hall M; Khatib Z; Kline C; MacDonald T; Mueller S; Faison SL; Allen JE; Naderer OJ; Ramage SC; Tarapore RS; McGovern SL; Khatua S; Zaky W; Gardner SL
Neuro Oncol; 2024 May; 26(Supplement_2):S155-S164. PubMed ID: 38400780
[TBL] [Abstract][Full Text] [Related]
6. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Arrillaga-Romany I; Gardner SL; Odia Y; Aguilera D; Allen JE; Batchelor T; Butowski N; Chen C; Cloughesy T; Cluster A; de Groot J; Dixit KS; Graber JJ; Haggiagi AM; Harrison RA; Kheradpour A; Kilburn LB; Kurz SC; Lu G; MacDonald TJ; Mehta M; Melemed AS; Nghiemphu PL; Ramage SC; Shonka N; Sumrall A; Tarapore RS; Taylor L; Umemura Y; Wen PY
J Clin Oncol; 2024 May; 42(13):1542-1552. PubMed ID: 38335473
[TBL] [Abstract][Full Text] [Related]
7. ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma.
Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Grand ML; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdes-Mora F; Rakotomalala A; Meignan S; Pasquier E; André N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
Cancer Res; 2023 May; ():OF1-OF17. PubMed ID: 37195023
[TBL] [Abstract][Full Text] [Related]
8. ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma.
Jackson ER; Duchatel RJ; Staudt DE; Persson ML; Mannan A; Yadavilli S; Parackal S; Game S; Chong WC; Jayasekara WSN; Le Grand M; Kearney PS; Douglas AM; Findlay IJ; Germon ZP; McEwen HP; Beitaki TS; Patabendige A; Skerrett-Byrne DA; Nixon B; Smith ND; Day B; Manoharan N; Nagabushan S; Hansford JR; Govender D; McCowage GB; Firestein R; Howlett M; Endersby R; Gottardo NG; Alvaro F; Waszak SM; Larsen MR; Colino-Sanguino Y; Valdés-Mora F; Rakotomalala A; Meignan S; Pasquier E; Andre N; Hulleman E; Eisenstat DD; Vitanza NA; Nazarian J; Koschmann C; Mueller S; Cain JE; Dun MD
Cancer Res; 2023 May; 83(14):2421-37. PubMed ID: 37145169
[TBL] [Abstract][Full Text] [Related]
9. Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials.
Vitanza NA; Monje M
Curr Treat Options Neurol; 2019 Jul; 21(8):37. PubMed ID: 31290035
[TBL] [Abstract][Full Text] [Related]
10. ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
Arrillaga-Romany I; Lassman A; McGovern SL; Mueller S; Nabors B; van den Bent M; Vogelbaum MA; Allen JE; Melemed AS; Tarapore RS; Wen PY; Cloughesy T
Neuro Oncol; 2024 May; 26(Supplement_2):S173-S181. PubMed ID: 38445964
[TBL] [Abstract][Full Text] [Related]
11. Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
Stein MN; Malhotra J; Tarapore RS; Malhotra U; Silk AW; Chan N; Rodriguez L; Aisner J; Aiken RD; Mayer T; Haffty BG; Newman JH; Aspromonte SM; Bommareddy PK; Estupinian R; Chesson CB; Sadimin ET; Li S; Medina DJ; Saunders T; Frankel M; Kareddula A; Damare S; Wesolowsky E; Gabel C; El-Deiry WS; Prabhu VV; Allen JE; Stogniew M; Oster W; Bertino JR; Libutti SK; Mehnert JM; Zloza A
J Immunother Cancer; 2019 May; 7(1):136. PubMed ID: 31118108
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
[TBL] [Abstract][Full Text] [Related]
13. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR
Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799
[TBL] [Abstract][Full Text] [Related]
14. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
[TBL] [Abstract][Full Text] [Related]
15. Diffuse Intrinsic Pontine Glioma (DIPG): Breakthrough and Clinical Perspective.
Perrone MG; Ruggiero A; Centonze A; Carrieri A; Ferorelli S; Scilimati A
Curr Med Chem; 2021; 28(17):3287-3317. PubMed ID: 32767913
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas.
Hipp SJ; Goldman S; Kaushal A; Krauze A; Citrin D; Glod J; Walker K; Shih JH; Sethumadhavan H; O'Neill K; Garvin JH; Glade-Bender J; Karajannis MA; Atlas MP; Odabas A; Rodgers LT; Peer CJ; Savage J; Camphausen KA; Packer RJ; Figg WD; Warren KE
J Neurooncol; 2020 Sep; 149(3):437-445. PubMed ID: 33040274
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma.
Duchatel RJ; Mannan A; Woldu AS; Hawtrey T; Hindley PA; Douglas AM; Jackson ER; Findlay IJ; Germon ZP; Staudt D; Kearney PS; Smith ND; Hindley KE; Cain JE; André N; La Madrid AM; Nixon B; De Iuliis GN; Nazarian J; Irish K; Alvaro F; Eisenstat DD; Beck A; Vitanza NA; Mueller S; Morris JC; Dun MD
Neurooncol Adv; 2021; 3(1):vdab169. PubMed ID: 34988452
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).
Monje M; Cooney T; Glod J; Huang J; Peer CJ; Faury D; Baxter P; Kramer K; Lenzen A; Robison NJ; Kilburn L; Vinitsky A; Figg WD; Jabado N; Fouladi M; Fangusaro J; Onar-Thomas A; Dunkel IJ; Warren KE
Neuro Oncol; 2023 Dec; 25(12):2262-2272. PubMed ID: 37526549
[TBL] [Abstract][Full Text] [Related]
19. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
[TBL] [Abstract][Full Text] [Related]
20. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
Arrillaga-Romany I; Odia Y; Prabhu VV; Tarapore RS; Merdinger K; Stogniew M; Oster W; Allen JE; Mehta M; Batchelor TT; Wen PY
Neuro Oncol; 2020 Jan; 22(1):94-102. PubMed ID: 31702782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
